WO2007079169A3 - Treatment for acute myeloid leukemia - Google Patents

Treatment for acute myeloid leukemia Download PDF

Info

Publication number
WO2007079169A3
WO2007079169A3 PCT/US2006/049466 US2006049466W WO2007079169A3 WO 2007079169 A3 WO2007079169 A3 WO 2007079169A3 US 2006049466 W US2006049466 W US 2006049466W WO 2007079169 A3 WO2007079169 A3 WO 2007079169A3
Authority
WO
WIPO (PCT)
Prior art keywords
myeloid leukemia
acute myeloid
treatment
patient
aml
Prior art date
Application number
PCT/US2006/049466
Other languages
French (fr)
Other versions
WO2007079169A2 (en
Inventor
Jeffrey S Miller
Carla Yunis
Original Assignee
3M Innovative Properties Co
Jeffrey S Miller
Carla Yunis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co, Jeffrey S Miller, Carla Yunis filed Critical 3M Innovative Properties Co
Publication of WO2007079169A2 publication Critical patent/WO2007079169A2/en
Publication of WO2007079169A3 publication Critical patent/WO2007079169A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a method of treating acute myeloid leukemia. Generally, the method includes administering to a patient with AML an amount of a TLR agonist compound effective to decrease the percentage of leukemic cells in the patient's peripheral blood or bone marrow.
PCT/US2006/049466 2005-12-28 2006-12-28 Treatment for acute myeloid leukemia WO2007079169A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75434005P 2005-12-28 2005-12-28
US60/754,340 2005-12-28

Publications (2)

Publication Number Publication Date
WO2007079169A2 WO2007079169A2 (en) 2007-07-12
WO2007079169A3 true WO2007079169A3 (en) 2007-08-30

Family

ID=38228845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/049466 WO2007079169A2 (en) 2005-12-28 2006-12-28 Treatment for acute myeloid leukemia

Country Status (1)

Country Link
WO (1) WO2007079169A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1653914A4 (en) 2003-08-12 2008-10-29 3M Innovative Properties Co Oxime substituted imidazo-containing compounds
ES2406730T3 (en) 2003-08-27 2013-06-07 3M Innovative Properties Company Imidazoquinolines substituted with aryloxy and arylalkylenoxy
JP2007504269A (en) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Method for treating CD5 + B cell lymphoma
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
EP1685129A4 (en) 2003-11-14 2008-10-22 3M Innovative Properties Co Oxime substituted imidazo ring compounds
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
WO2005051317A2 (en) 2003-11-25 2005-06-09 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US8735421B2 (en) 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
US7943609B2 (en) 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
JP2008538550A (en) 2005-04-01 2008-10-30 コーリー ファーマシューティカル グループ，インコーポレイテッド 1-Substituted pyrazolo (3,4-c) cyclic compounds as modulators of cytokine biosynthesis for treating viral infections and neoplastic diseases
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
WO2018078620A1 (en) 2016-10-25 2018-05-03 Urogen Pharma Ltd. Immunomodulating treatments of body cavities

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US20040023870A1 (en) * 2000-01-21 2004-02-05 Douglas Dedera Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US20040091491A1 (en) * 2002-08-15 2004-05-13 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US20040141950A1 (en) * 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
US20040162309A1 (en) * 2003-02-13 2004-08-19 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like receptor 8
US20050281813A1 (en) * 2002-02-14 2005-12-22 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023870A1 (en) * 2000-01-21 2004-02-05 Douglas Dedera Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US20050281813A1 (en) * 2002-02-14 2005-12-22 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US20040091491A1 (en) * 2002-08-15 2004-05-13 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US20040141950A1 (en) * 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
US20040162309A1 (en) * 2003-02-13 2004-08-19 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like receptor 8

Also Published As

Publication number Publication date
WO2007079169A2 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
WO2007079169A3 (en) Treatment for acute myeloid leukemia
WO2007079202A3 (en) Treatment for acute lymhoblastic leukemia
WO2007079146A8 (en) Treatment for non-hodgkin's lymphoma
WO2007079171A3 (en) Treatment for hodgkin's lymphoma
EP2100614B8 (en) Antibody against PDGFR-alpha for use in the treatment of tumours
MXPA05009694A (en) Methods of improving skin quality.
WO2005107730A3 (en) Cysteamines for treating complications of hypercholesterolemia and diabetes
WO2005107771A3 (en) Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer
EP2308885A3 (en) Novel compounds and methods for therapy
WO2004004658A3 (en) Methods and compositions relating to isoleucine boroproline compounds
IL204561A (en) Device for treating bodily tissues with medicinal substance
TW200701977A (en) Novel use of peptide compounds for treating pain in painful diabetic neuropathy
TW200714283A (en) Method and composition for treating peripheral vascular diseases
MX2009009417A (en) Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain.
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2006128125A3 (en) Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
EA200870088A1 (en) APPLICATION OF BENZO-CONDENSED HETEROCYCLIC SULFAMIDE DERIVATIVES TO REDUCE LIPPLE AND GLUCOSE LEVELS IN THE BLOOD
WO2005113016A3 (en) Modulation of glucose-6-phosphatase translocase expression
HK1091739A1 (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
WO2005089515A3 (en) Methods for the treatment of synucleinopathies
WO2006019978A3 (en) Compositions and methods for diagnosis and treatment of epilepsy
WO2005060960A3 (en) Use of histamine to treat bone disease
AU2003250190A1 (en) Combination of an aromatase inhibitor with a bisphosphonate
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
WO2006091587A3 (en) Use of minoxidil sulfate as an anti-tumor drug

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06848266

Country of ref document: EP

Kind code of ref document: A2